HDAC9 and neoplasm: Extensive prior research has shown that HDAC inhibition modulates the tumor immune microenvironment by decreasing the number of suppressive innate immune cells and altering their T cell suppressive function7,32–34, resulting in complementary clinical activity with anti-PD1 immunotherapy.